Online inquiry

IVTScrip™ mRNA-Human Apelin, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK23105MR)

This product GTTS-WK23105MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the Apelin protein. This product can be used in Endothelial cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_005161.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 187
UniProt ID Q9ULZ1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human Apelin, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK23105MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK27155MR IVTScrip™ mRNA-Human ARMC4, (Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ARMC4
GTTS-WK20857MR IVTScrip™ mRNA-Human AMOTL2, (Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMOTL2
GTTS-WK14837MR IVTScrip™ mRNA-Human alpha-SMA, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA alpha-SMA
GTTS-WK14308MR IVTScrip™ mRNA-Human ADAMTSL1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADAMTSL1
GTTS-WK16136MR IVTScrip™ mRNA-Human ANKRD7, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD7
GTTS-WK15224MR IVTScrip™ mRNA-Human ANKRD39, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANKRD39
GTTS-WK18201MR IVTScrip™ mRNA-Human ANKRD13D, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD13D
GTTS-WK13139MR IVTScrip™ mRNA-Human ADGRE5, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADGRE5
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW